Literature DB >> 10516307

Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

D M Hartley1, D M Walsh, C P Ye, T Diehl, S Vasquez, P M Vassilev, D B Teplow, D J Selkoe.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is thought to be caused in part by the age-related accumulation of amyloid beta-protein (Abeta). The presence of neuritic plaques containing abundant Abeta-derived amyloid fibrils in AD brain tissue supports the concept that fibril accumulation per se underlies neuronal dysfunction in AD. Recent observations have begun to challenge this assumption by suggesting that earlier Abeta assemblies formed during the process of fibrillogenesis may also play a role in AD pathogenesis. Here, we present the novel finding that protofibrils (PF), metastable intermediates in amyloid fibril formation, can alter the electrical activity of neurons and cause neuronal loss. Both low molecular weight Abeta (LMW Abeta) and PF reproducibly induced toxicity in mixed brain cultures in a time- and concentration-dependent manner. No increase in fibril formation during the course of the experiments was observed by either Congo red binding or electron microscopy, suggesting that the neurotoxicity of LMW Abeta and PF cannot be explained by conversion to fibrils. Importantly, protofibrils, but not LMW Abeta, produced a rapid increase in EPSPs, action potentials, and membrane depolarizations. These data suggest that PF have inherent biological activity similar to that of mature fibrils. Our results raise the possibility that the preclinical and early clinical progression of AD is driven in part by the accumulation of specific Abeta assembly intermediates formed during the process of fibrillogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516307      PMCID: PMC6782787     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

3.  Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins.

Authors:  W Xia; J Zhang; D Kholodenko; M Citron; M B Podlisny; D B Teplow; C Haass; P Seubert; E H Koo; D J Selkoe
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

4.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Authors:  C A Lemere; J K Blusztajn; H Yamaguchi; T Wisniewski; T C Saido; D J Selkoe
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

Review 6.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.

Authors:  J D Harper; P T Lansbury
Journal:  Annu Rev Biochem       Date:  1997       Impact factor: 23.643

7.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

Authors:  S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

8.  Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay.

Authors:  W E Klunk; R F Jacob; R P Mason
Journal:  Anal Biochem       Date:  1999-01-01       Impact factor: 3.365

9.  beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity.

Authors:  M P Mattson; B Cheng; D Davis; K Bryant; I Lieberburg; R E Rydel
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

Review 10.  Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities.

Authors:  J L Cummings; H V Vinters; G M Cole; Z S Khachaturian
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

View more
  251 in total

1.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

2.  Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta.

Authors:  Minako Hoshi; Michio Sato; Shinichiro Matsumoto; Akihiko Noguchi; Kaori Yasutake; Natsuko Yoshida; Kazuki Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

3.  From conversion to aggregation: protofibril formation of the prion protein.

Authors:  Mari L DeMarco; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

4.  Molecular dynamics simulation of amyloid beta dimer formation.

Authors:  B Urbanc; L Cruz; F Ding; D Sammond; S Khare; S V Buldyrev; H E Stanley; N V Dokholyan
Journal:  Biophys J       Date:  2004-10       Impact factor: 4.033

5.  Single-particle characterization of Aβ oligomers in solution.

Authors:  Erik C Yusko; Panchika Prangkio; David Sept; Ryan C Rollings; Jiali Li; Michael Mayer
Journal:  ACS Nano       Date:  2012-06-21       Impact factor: 15.881

6.  Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.

Authors:  Douglas J Martin; Marina Ramirez-Alvarado
Journal:  Amyloid       Date:  2010-09       Impact factor: 7.141

7.  Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility.

Authors:  Li Ling Lee; HyungHo Ha; Young-Tae Chang; Matthew P DeLisa
Journal:  Protein Sci       Date:  2009-02       Impact factor: 6.725

8.  Expression and purification of amyloid-beta peptides from Escherichia coli.

Authors:  Kanchan Garai; Scott L Crick; Sourajit M Mustafi; Carl Frieden
Journal:  Protein Expr Purif       Date:  2009-02-20       Impact factor: 1.650

9.  The Aggregation Paths and Products of Aβ42 Dimers Are Distinct from Those of the Aβ42 Monomer.

Authors:  Tiernan T O'Malley; William M Witbold; Sara Linse; Dominic M Walsh
Journal:  Biochemistry       Date:  2016-10-26       Impact factor: 3.162

10.  Role of Apolipoprotein E in β-Amyloidogenesis: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO FIBRIL CONVERSION OF Aβ IN VITRO AND BRAIN Aβ DEPOSITION IN VIVO.

Authors:  Yukiko Hori; Tadafumi Hashimoto; Hidetoshi Nomoto; Bradley T Hyman; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.